첫 페이지 News 본문

Takeda Pharmaceuticals stated that as part of its multi-year plan to support growth and improve profit margins, the company will incur a one-time restructuring fee of 140 billion yen in the 2024 fiscal year, which has been reflected in the full year forecast. Takeda Pharmaceuticals stated that it will include measures to optimize its workforce, and specific details will be provided in& Quota; At the appropriate time& Quota; Decision. (Bloomberg)
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

海角七号 注册会员
  • Follow

    0

  • Following

    1

  • Articles

    29